Background: This is a single center, observational prospective study that aimed primarily to study role of
Galectin-3 (as a simple marker of inflammation and fibrosis) in prediction of the occurrence of LV remodeling after
anterior ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI)
for Left anterior descending artery (LAD) or left main (LM) as infarct related artery. Patients and methods: The
present study protocol yielded 2 groups of patients: First group, consists of patients found to have LVR with high
galectin 3 levels at baseline and 6 months follow up after anterior STEMI treated with primary PCI to LAD or LM.
Second group consists of patients found to have no LVR with low levels of galectin 3 levels at baseline and 6
months follow up after anterior STEMI treated with primary PCI to LAD or LM. Results: Baseline and 6 months EF
were significantly higher in the no LVR (57±8 &55 ±8 respectively) group than the LVR group (44 ±7&37 ±8
respectively), P values were |
